1. Home
  2. COEP vs FRSX Comparison

COEP vs FRSX Comparison

Compare COEP & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • FRSX
  • Stock Information
  • Founded
  • COEP 2017
  • FRSX N/A
  • Country
  • COEP United States
  • FRSX Israel
  • Employees
  • COEP N/A
  • FRSX N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • COEP Health Care
  • FRSX Technology
  • Exchange
  • COEP Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • COEP 32.4M
  • FRSX 31.1M
  • IPO Year
  • COEP N/A
  • FRSX 2017
  • Fundamental
  • Price
  • COEP $13.01
  • FRSX $0.96
  • Analyst Decision
  • COEP
  • FRSX
  • Analyst Count
  • COEP 0
  • FRSX 0
  • Target Price
  • COEP N/A
  • FRSX N/A
  • AVG Volume (30 Days)
  • COEP 111.7K
  • FRSX 168.4K
  • Earning Date
  • COEP 03-25-2025
  • FRSX 03-26-2025
  • Dividend Yield
  • COEP N/A
  • FRSX N/A
  • EPS Growth
  • COEP N/A
  • FRSX N/A
  • EPS
  • COEP N/A
  • FRSX N/A
  • Revenue
  • COEP N/A
  • FRSX $473,000.00
  • Revenue This Year
  • COEP N/A
  • FRSX N/A
  • Revenue Next Year
  • COEP N/A
  • FRSX N/A
  • P/E Ratio
  • COEP N/A
  • FRSX N/A
  • Revenue Growth
  • COEP N/A
  • FRSX 3.28
  • 52 Week Low
  • COEP $2.31
  • FRSX $0.57
  • 52 Week High
  • COEP $13.70
  • FRSX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • COEP 64.98
  • FRSX 42.63
  • Support Level
  • COEP $8.65
  • FRSX $0.88
  • Resistance Level
  • COEP $13.50
  • FRSX $1.05
  • Average True Range (ATR)
  • COEP 1.52
  • FRSX 0.09
  • MACD
  • COEP -0.10
  • FRSX -0.01
  • Stochastic Oscillator
  • COEP 86.34
  • FRSX 23.96

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its advanced systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: